Home › Companies › LARIMAR THERAPEUTICS INC. › 2023-2024

LARIMAR THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and LARIMAR THERAPEUTICS INC.’s Form 8-K, filed May 31, 2024 (Item 5.07 on EDGAR). Page generated November 7, 2026.

  • 6Ballot items
  • 114Asset managers
  • 732Fund votes
  • May 29, 2024Meeting date

Results at a glance

Meeting of May 29, 2024: 6 items on LARIMAR THERAPEUTICS INC.’s Form 8-K, filed May 31, 2024: 3 approved · 3 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore LARIMAR THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by LARIMAR THERAPEUTICS INC.

These tallies are LARIMAR THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 31, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

LARIMAR THERAPEUTICS INC. — official shareholder meeting results, meeting held May 29, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jonathan Leff 40,728,411---- 10,501,0698,332,013 80%Not verified—
Elect Director: Jeffrey W. Sherman, M.D., FACP 51,056,220---- 173,2608,332,013 99.6%Not verified—
2. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2023 48,754,0882,352,496122,896 --8,332,013 95%Approved—
3. Ratification of Independent Registered Public Accountant 59,557,7432,7351,015 --0 99.9%Approved—
4. Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation, as amended 50,900,686279,97648,818 --8,332,013 99.4%Approved—
5. Approval of an adjournment of the Annual Meeting 49,740,7061,484,5434,231 --8,332,013 97%Not verified—

Source: LARIMAR THERAPEUTICS INC., Form 8-K, filed with the SEC on May 31, 2024 — read the filing on EDGAR.

How asset managers voted at the LARIMAR THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 114 asset managers that disclosed a LARIMAR THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Jeffrey W. Sherman, M.D., FACP

Outcome not verifiedFund totals may overlapDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 51,056,220WITHHELD: 173,260
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Election of Class I Directors for a Three-Year Term Expiring in 2027: Jeffrey W. Sherman, M.D., FACP

LARIMAR THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey W. Sherman, M.D., FACP”): 51,056,220 for, 173,260 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 40 asset managers voting on “Election of Class I Directors for a Three-Year Term Expiring in 2027: Jeffrey W. Sherman, M.D., FACP” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,334,7110 00For
BlackRock817,5360 00For
Fidelity620,2960 00For
ALGER FUNDS468,1820 00For
ALGER PORTFOLIOS200,5440 00For
ALGER INSTITUTIONAL FUNDS153,6100 00For
DRIEHAUS MUTUAL FUNDS88,7270 00For
Charles Schwab83,0090 00For
QUANTITATIVE MASTER SERIES LLC49,7900 00For
RBB FUND, INC.49,6760 00For
Dimensional47,0230 00For
TIAA46,9360 00For
American Century44,9010 00For
BRIDGEWAY FUNDS INC44,0340 00For
Brinker Capital Destinations Trust32,0520 00For
Lincoln Financial23,8540 00For
AIG/SunAmerica12,8250 00For
Equitable12,6970 00For
Northern Trust12,1070 00For
Pacific Life11,1490 00For
Bridge Builder Trust10,7610 00For
John Hancock9,1790 00For
Voya8,6820 00For
Jackson National7,7430 00For
ProShares5,2440 00For

Fund voting reports, all 40 managers: 5,218,714 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors for a Three-Year Term Expiring in 2027: Jeffrey W. Sherman, M.D., FACP” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Altium Capital Management LP695,0000 00For

Institutional-manager reports, all 1 managers: 695,000 for.

2. Elect Director: Jonathan Leff

Outcome not verifiedFund totals may overlapDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 40,728,411WITHHELD: 10,501,069
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Election of Class I Directors for a Three-Year Term Expiring in 2027: Jonathan Leff

LARIMAR THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jonathan Leff”): 40,728,411 for, 10,501,069 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 40 asset managers voting on “Election of Class I Directors for a Three-Year Term Expiring in 2027: Jonathan Leff” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,334,7110 00For
BlackRock00 0817,536Withhold
Fidelity620,2960 00For
ALGER FUNDS00 0468,182Withhold
ALGER PORTFOLIOS00 0200,544Withhold
ALGER INSTITUTIONAL FUNDS00 0153,610Withhold
DRIEHAUS MUTUAL FUNDS00 088,727Withhold
Charles Schwab00 083,009Withhold
QUANTITATIVE MASTER SERIES LLC00 049,790Withhold
RBB FUND, INC.00 049,676Withhold
Dimensional00 047,023Withhold
TIAA00 046,936Withhold
American Century00 044,901Withhold
BRIDGEWAY FUNDS INC00 044,034Withhold
Brinker Capital Destinations Trust00 032,052Withhold
Lincoln Financial00 023,854Withhold
AIG/SunAmerica00 012,825Withhold
Equitable00 012,697Withhold
Northern Trust00 012,107Withhold
Pacific Life00 011,149Withhold
Bridge Builder Trust00 010,761Withhold
John Hancock00 09,179Withhold
Voya00 08,682Withhold
Jackson National00 07,743Withhold
ProShares00 05,244Withhold

Fund voting reports, all 40 managers: 2,957,257 for, 2,261,457 withheld. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors for a Three-Year Term Expiring in 2027: Jonathan Leff” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Altium Capital Management LP695,0000 00For

Institutional-manager reports, all 1 managers: 695,000 for.

3. 4. Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation, as amended

Official resultFund totals may overlapCORPORATE GOVERNANCEReported outcome: Approved

99.4% Approved · of votes cast

FOR 99.4%
FOR: 50,900,686AGAINST: 279,976
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Approval of an amendment to our Ninth Amended and Restated Certificate of Incorporation, as amended, to reflect Delaware law provisions regarding officer exculpation

LARIMAR THERAPEUTICS INC.’s own tally for this item (“4. Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation, as amended”): 50,900,686 for, 279,976 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved an amendment to the Company's Ninth Amended and Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation, as follows:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 40 asset managers voting on “Approval of an amendment to our Ninth Amended and Restated Certificate of Incorporation, as amended, to reflec” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,334,7110 00For
BlackRock817,5360 00For
Fidelity620,2960 00For
ALGER FUNDS468,1820 00For
ALGER PORTFOLIOS200,5440 00For
ALGER INSTITUTIONAL FUNDS153,6100 00For
DRIEHAUS MUTUAL FUNDS88,7270 00For
Charles Schwab83,0090 00For
QUANTITATIVE MASTER SERIES LLC49,7900 00For
RBB FUND, INC.49,6760 00For
Dimensional47,0230 00For
TIAA46,9360 00For
American Century44,9010 00For
BRIDGEWAY FUNDS INC44,0340 00For
Brinker Capital Destinations Trust32,0520 00For
Lincoln Financial23,8540 00For
AIG/SunAmerica12,8250 00For
Equitable12,6970 00For
Northern Trust12,1070 00For
Pacific Life11,1490 00For
Bridge Builder Trust10,7610 00For
John Hancock9,1790 00For
Voya8,6820 00For
Jackson National7,7430 00For
ProShares5,2440 00For

Fund voting reports, all 40 managers: 5,213,520 for, 5,194 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “Approval of an amendment to our Ninth Amended and Restated Certificate of Incorporation, as amended, to reflec” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Altium Capital Management LP695,0000 00For

Institutional-manager reports, all 1 managers: 695,000 for.

4. 5. Approval of an adjournment of the Annual Meeting

Outcome not verifiedFund totals may overlapCORPORATE GOVERNANCEReported outcome: Not verified

97% Majority: yes · of votes cast

FOR 97%
FOR: 49,740,706AGAINST: 1,484,543
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 4

LARIMAR THERAPEUTICS INC.’s own tally for this item (“5. Approval of an adjournment of the Annual Meeting”): 49,740,706 for, 1,484,543 against, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 40 asset managers voting on “Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meet” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,334,7110 00For
BlackRock817,5360 00For
Fidelity620,2960 00For
ALGER FUNDS468,1820 00For
ALGER PORTFOLIOS200,5440 00For
ALGER INSTITUTIONAL FUNDS153,6100 00For
DRIEHAUS MUTUAL FUNDS88,7270 00For
Charles Schwab083,009 00Against
QUANTITATIVE MASTER SERIES LLC49,7900 00For
RBB FUND, INC.49,6760 00For
Dimensional47,0230 00For
TIAA46,9360 00For
American Century44,9010 00For
BRIDGEWAY FUNDS INC44,0340 00For
Brinker Capital Destinations Trust31,590462 00For
Lincoln Financial2,55421,300 00Mixed
AIG/SunAmerica12,8250 00For
Equitable12,6970 00For
Northern Trust12,1070 00For
Pacific Life11,1490 00For
Bridge Builder Trust10,7610 00For
John Hancock9,1790 00For
Voya8,6820 00For
Jackson National7,7430 00For
ProShares5,2440 00For

Fund voting reports, all 40 managers: 5,108,943 for, 109,771 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meet” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Altium Capital Management LP695,0000 00For

Institutional-manager reports, all 1 managers: 695,000 for.

5. 2. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2023

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 48,754,088AGAINST: 2,352,496
Details: description as filed, official tally, votes by 114 asset managers

Description as filed by funds: Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2023

LARIMAR THERAPEUTICS INC.’s own tally for this item (“2. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2023”): 48,754,088 for, 2,352,496 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers in 2023, as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 40 asset managers voting on “Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2023” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,334,7110 00For
BlackRock817,5360 00For
Fidelity620,2960 00For
ALGER FUNDS0468,182 00Against
ALGER PORTFOLIOS0200,544 00Against
ALGER INSTITUTIONAL FUNDS0153,610 00Against
DRIEHAUS MUTUAL FUNDS88,7270 00For
Charles Schwab83,0090 00For
QUANTITATIVE MASTER SERIES LLC49,7900 00For
RBB FUND, INC.49,6760 00For
Dimensional47,0230 00For
TIAA46,9360 00For
American Century044,901 00Against
BRIDGEWAY FUNDS INC044,034 00Against
Brinker Capital Destinations Trust32,0520 00For
Lincoln Financial23,8540 00For
AIG/SunAmerica12,8250 00For
Equitable12,6970 00For
Northern Trust12,1070 00For
Pacific Life11,1490 00For
Bridge Builder Trust10,7610 00For
John Hancock9,1790 00For
Voya8,6820 00For
Jackson National7,7430 00For
ProShares5,2440 00For

Fund voting reports, all 40 managers: 4,300,576 for, 918,138 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 85 asset managers voting on “Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2023” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)21,231,9740 00For
RA CAPITAL MANAGEMENT, L.P.6,045,3500 00For
Janus Henderson3,931,5280 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.1,471,5000 00For
Verition Fund Management LLC1,439,7560 00For
BlackRock980,1423,210 00For
DRIEHAUS CAPITAL MANAGEMENT LLC843,6110 00For
Citadel827,2980 00For
FRED ALGER MANAGEMENT, LLC0825,096 00Against
MANGROVE PARTNERS IM, LLC813,9010 00For
Goldman Sachs795,5240 00For
Altium Capital Management LP695,0000 00For
GEODE CAPITAL MANAGEMENT, LLC686,9830 00For
DAFNA Capital Management LLC656,3730 00For
RTW INVESTMENTS, LP625,9100 00For
Alyeska Investment Group, L.P.0500,159 00Against
State Street495,135479 00For
Woodline Partners LP480,7530 00For
Point72457,3490 00For
Northern Trust268,960202 00For
Two Sigma267,7500 00For
Renaissance229,5980 00For
UBS202,7830 00For
Allianz0140,560 00Against
MARSHALL WACE, LLP099,617 00Against

Institutional-manager reports, all 85 managers: 44,137,157 for, 1,691,358 against, 1,000 not voted. Showing the 25 largest; see all in the interactive database.

6. 3. Ratification of Independent Registered Public Accountant

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 59,557,743AGAINST: 2,735
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Ratification of Appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accounting Firm for the 2024 Fiscal Year

LARIMAR THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Independent Registered Public Accountant”): 59,557,743 for, 2,735 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2024 fiscal year was ratified, as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 40 asset managers voting on “Ratification of Appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accounting Firm” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,334,7110 00For
BlackRock817,5360 00For
Fidelity620,2960 00For
ALGER FUNDS468,1820 00For
ALGER PORTFOLIOS200,5440 00For
ALGER INSTITUTIONAL FUNDS153,6100 00For
DRIEHAUS MUTUAL FUNDS88,7270 00For
Charles Schwab83,0090 00For
QUANTITATIVE MASTER SERIES LLC49,7900 00For
RBB FUND, INC.49,6760 00For
Dimensional47,0230 00For
TIAA46,9360 00For
American Century44,9010 00For
BRIDGEWAY FUNDS INC44,0340 00For
Brinker Capital Destinations Trust32,0520 00For
Lincoln Financial23,8540 00For
AIG/SunAmerica12,8250 00For
Equitable12,6970 00For
Northern Trust12,1070 00For
Pacific Life11,1490 00For
Bridge Builder Trust10,7610 00For
John Hancock9,1790 00For
Voya8,6820 00For
Jackson National7,7430 00For
ProShares5,2440 00For

Fund voting reports, all 40 managers: 5,218,714 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “Ratification of Appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accounting Firm” at LARIMAR THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Altium Capital Management LP695,0000 00For

Institutional-manager reports, all 1 managers: 695,000 for.

Largest LARIMAR THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 63,802,017 shares outstanding at the time of that meeting.

Fund voting reports: top LARIMAR THERAPEUTICS INC. shareholders by shares voted on “Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2023”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 3.66%
2BlackRock 1.28%
3Fidelity 0.97%
4ALGER FUNDS 0.73%
5ALGER PORTFOLIOS 0.31%
6ALGER INSTITUTIONAL FUNDS 0.24%
7DRIEHAUS MUTUAL FUNDS 0.14%
8Charles Schwab 0.13%
9QUANTITATIVE MASTER SERIES LLC 0.08%
10RBB FUND, INC. 0.08%
Institutional-manager reports: top LARIMAR THERAPEUTICS INC. shareholders by shares voted on “Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2023”, 2023-2024
#Asset manager % of shares outstanding
1DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 33.28%
2RA CAPITAL MANAGEMENT, L.P. 9.48%
3Janus Henderson 6.16%
4ADAGE CAPITAL PARTNERS GP, L.L.C. 2.31%
5Verition Fund Management LLC 2.26%
6BlackRock 1.54%
7DRIEHAUS CAPITAL MANAGEMENT LLC 1.32%
8Citadel 1.30%
9FRED ALGER MANAGEMENT, LLC 1.29%
10MANGROVE PARTNERS IM, LLC 1.28%

Reported LARIMAR THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

LARIMAR THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder % outstanding Disclosure
BlackRock 5.23% 13F
Vanguard Group 4.84% 13F
Goldman Sachs 2.47% 13F
Citadel Advisors 2.02% 13F
Geode Capital 1.36% 13F
Millennium Management 1.23% 13F
State Street 0.99% 13F
Renaissance Technologies 0.79% 13F
Point72 0.69% 13F
Northern Trust 0.46% 13F

Percentages above are of 63,802,017 shares outstanding, as reported by LARIMAR THERAPEUTICS INC. on its Form 10-Q dated May 7, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LARIMAR THERAPEUTICS INC.’s 10-Q dated May 7, 2024. This page is a static snapshot rebuilt weekly on November 7, 2026; a live search always shows the current data.

At LARIMAR THERAPEUTICS INC.'s shareholder meeting held May 29, 2024, in the 2023-2024 proxy season, 114 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 732 separate fund positions. On the most widely held item on that ballot — Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2023 — LARIMAR THERAPEUTICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: LARIMAR THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 31, 2024.

LARIMAR THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.